The Evseenko Laboratory is dedicated to translating fundamental scientific discoveries into targeted therapies that address both widespread diseases and the most pressing challenges of aging. Our mission encompasses prevention, disease modification, and curative strategies, with the overarching goal of extending health span so that advances in medicine translate into meaningful improvements in function, vitality, and quality of life.
Central to our translational work, our team has invented a first-in-class small molecule CX-011, designed to treat osteoarthritis by modulating inflammation, immune dysregulation, and cartilage breakdown. Unlike conventional therapies that primarily alleviate pain, CX-011 directly targets the biological mechanisms underlying joint degeneration. It is currently in a Phase 1/2a clinical trial, demonstrating potential for structural protection, functional improvement, and reduced reliance on symptomatic medications. In parallel, we developed Plurocart, a pluripotent stem cell-derived cartilage therapy engineered to restore functional tissue, reduce chronic inflammation, and promote repair. Plurocart is advancing toward clinical trials in 2026 and exemplifies a disease-modifying approach to degenerative joint and musculoskeletal disorders.
Building on these achievements, our laboratory launched the Arthritis Plus Program at USC in collaboration with Colorado State University. This innovative platform uses aged canine models to develop interventions that prevent osteoarthritis and address associated age-related conditions such as frailty, metabolic dysfunction, and cognitive decline. Our preclinical research further includes development of novel small molecules for idiopathic pulmonary fibrosis, targeting inflammation and fibrosis with success in preserving lung structure and function. Beyond these initiatives, the lab is actively exploring next-generation therapies for eye diseases, tendinopathies, cardiovascular and vascular disorders, septic shock in aged patients, and cancer-related complications.
Through the invention and development of breakthrough therapies and their advancement from discovery to clinical evaluation, the Evseenko Laboratory exemplifies how pioneering biology can be translated into interventions that enhance health span, redefine standards of care, and improve patient outcomes.